$NLSP News
Last published 1y ago
- 1y agoNLSPNLSPWNCELNLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of MergerPR NewswireNewcelX Ltd. ("NewcelX" or the "Company") completed the previously announced merger transaction, pursuant to that certain Agreement of Merger and...
- 1y agoNLSPNLSPWNLS Pharmaceutics Expands CNS Pipeline With AEX-6xx Series Developed by Aexon LabsPR NewswireNLS Pharmaceutics Ltd. (Nasdaq: NLSP)(Nasdaq: NLSPW) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system and...
- 1y agoNLSPNLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following MergerPR NewswireNLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS" or the "Company"), a biopharmaceutical company focused on developing innovative therapies for central...
- 1y agoNLSPNLSPWNLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection with Proposed Merger with KadimastemPR NewswireNLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the...
- 1y agoNLSPNLSPWNLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's SharesPR NewswireNLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company") and Kadimastem Ltd. (TASE: KDST) ("Kadimastem") today announced that,...
- 1y agoNLSPNLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell TherapiesPR NewswireNLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system and...
- 1y agoNLSPNLSPWNLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025PR NewswireNLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on central...
- 1y agoNLSPNLSPWKadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed MergerPR NewswireNLS Pharmaceutics Ltd. (Nasdaq: NLSP)(Nasdaq: NLSPW) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system...
- 1y agoNLSPNLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes PatientsPR NewswireNLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS" or the "Company") today announced that its merger partner Kadimastem Ltd. (TASE: KDST) ("Kadimastem")...
- 1y agoNLSPNLS Pharmaceutics Highlights Continued Progress in iTOL-102 Diabetes Program as BIRD Foundation Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell TherapyPR NewswireNLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS"), a Swiss clinical-stage biopharmaceutical company focused on central nervous system disorders, today...
- 1y agoNLSPNLS Pharmaceutics and Kadimastem Announce Pricing and Closing of $1 Million Equity FinancingPR NewswireNLS Pharmaceutics Ltd. (NASDAQ: NLSP) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on developing therapies for...
- 1y agoNLSPNLS Pharmaceutics CEO Issues Letter to ShareholdersPR NewswireNLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central...
- 1y agoNLSPNLS Pharmaceutics to Present New Data on the Dual Efficacy of Mazindol ER in Fentanyl Reward and Withdrawal at the 2025 ASCP Annual MeetingPR NewswireNLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on central nervous system ("CNS") disorders,...
- 1y agoNLSPNLSPWNLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal ModelsPR NewswireNLS Pharmaceutics Ltd. (Nasdaq: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on...
- 1y agoNLSPNLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility AgreementACCESS NewswireThe equity financing is at a 10% premium to the market share price1 ZÜRICH, SWITZERLAND / ACCESS Newswire / March 31, 2025 / NLS Pharmaceutics Ltd. , a Swiss
- 1y agoNLSPNLS Pharmaceutics CEO Issues Letter to ShareholdersPR NewswireNLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central...
- 1y agoNLSPNLSPWNLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist PlatformPR NewswireNLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), in collaboration with Aexon Labs Inc. ("Aexon Labs"), is pleased to...
- 1y agoNLSPKadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes TreatmentPR NewswireNLS Pharmaceutics Ltd. (Nasdaq: NLSP) ("NLS") and Kadimastem Ltd. (TASE: KDST) ("Kadimastem"), a clinical-stage company specializing in...
- 1y agoNLSPNLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 TherapiesPR NewswireNLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of...
- 1y agoNLSPKadimastem Shareholders Approved the Merger with NLS PharmaceuticsPR NewswireNLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of...
- 1y agoNLSPNLSPWNLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual MeetingPR NewswireNLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on...
- 1y agoNLSPNLSPWNLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl DependencePR NewswireNLS Pharmaceutics Ltd. (NASDAQ: NLSP) (NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to...
- 1y agoNLSPKadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLSPR NewswireNLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of...
- 1y agoNLSPNLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market Share Price as of Jan 6, 2025PR NewswireNLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of...
- 1y agoNLSPNLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed MergerPR NewswireNLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of...
- 1y agoNLSPNLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes TreatmentACCESS NewswireThis submission comes after successful INTERACT meeting with the FDA earlier this year.NLS Pharmaceutics and Kadimastem working to close merger by the end of January 2025 ZURICH, SWITZERLAND AND NESS ZIONA, ISRAEL /
- 1y agoNLSPNLS Pharmaceutics CEO Issues Letter to ShareholdersACCESS NewswireZURICH, SWITZERLAND / ACCESSWIRE / December 11, 2024 / NLS Pharmaceutics Ltd. , a Swiss clinical-stage biopharmaceutical company focused on the
- 1y agoNLSPNLSPWNLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the MarketPR NewswireNLS Pharmaceutics Ltd. (Nasdaq: NLSP) (Nasdaq: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the...
- 1y agoNLSPNLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological DisordersACCESS NewswireZÜRICH, SWITZERLAND / ACCESSWIRE / December 3, 2024 / NLS Pharmaceutics Ltd. , a biopharmaceutical company, is pleased to share preclinical data demonstrating the potential of its
- 1y agoNLSPNLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological DisordersACCESS NewswireZÜRICH, SWITZERLAND / ACCESSWIRE / November 18, 2024 / NLS Pharmaceutics Ltd. , a Swiss clinical-stage biopharmaceutical company focused on the
- 2y agoNLSPNLS Pharmaceutics and Kadimastem Enter into a Definitive Merger AgreementACCESS NewswireZURICH, SWITZERLAND and NESS ZIONA, ISRAEL / ACCESSWIRE / November 4, 2024 / NLS Pharmaceutics Ltd. , a biopharmaceutical company, and Kadimastem Ltd.
- 2y agoNLSPNLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing RequirementsACCESS NewswireZURICH, SWITZERLAND / ACCESSWIRE / October 28, 2024 / NLS Pharmaceutics Ltd. , a Swiss clinical-stage biopharmaceutical company focused on the
- 2y agoNLSPNLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin DependenceACCESS NewswireZURICH, SWITZERLAND / ACCESSWIRE / October 21, 2024 / NLS Pharmaceutics Ltd. , a Swiss clinical-stage biopharmaceutical company dedicated to
- 2y agoNLSPNLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing RulesACCESS NewswireZURICH, SWITZERLAND / ACCESSWIRE / October 15, 2024 / NLS Pharmaceutics Ltd. , a Swiss clinical-stage biopharmaceutical company focused on the
- 2y agoNLSPNLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share SplitACCESS NewswireZURICH, SWITZERLAND / ACCESSWIRE / September 25, 2024 / NLS Pharmaceutics Ltd. , a Swiss clinical-stage biopharmaceutical company focused on the
- 2y agoNLSPNLS Pharmaceutics and Kadimastem Announce Binding Term Sheet to MergeACCESS NewswireThe proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical development and focused on advancing Kadimastem's allogeneic cell therapy platformEach of
- 2y agoNLSPNLS Pharmaceutics Announces Registered Direct OfferingACCESS NewswireZURICH, SWITZERLAND / ACCESSWIRE / June 28, 2024 / NLS Pharmaceutics Ltd. , a Swiss clinical-stage biopharmaceutical company focused on the
- 2y agoNLSPNLS Pharmaceutics Announces Promising Preclinical Results for Parkinson's Disease TreatmentsACCESS NewswireZURICH, SWITZERLAND / ACCESSWIRE / June 27, 2024 / NLS Pharmaceutics Ltd. , a Swiss clinical-stage biopharmaceutical company dedicated to pioneering
- 2y agoNLSPNasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing RequirementsACCESS NewswireZURICH, SWITZERLAND / ACCESSWIRE / June 25, 2024 / NLS Pharmaceutics Ltd. , a leading Swiss biopharmaceutical company dedicated to pioneering
- 2y agoNLSPNLS Pharmaceutics Announces Publication of New Patent Application for Next-Gen Dual Non-Sulfonamide Orexin Receptor Agonists (DOXA)ACCESS NewswireZURICH, SWITZERLAND / ACCESSWIRE / June 11, 2024 / NLS Pharmaceutics Ltd. , a Swiss clinical-stage biopharmaceutical company dedicated to pioneering
- 2y agoNLSPNLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol's Neuroprotective Effects in Narcoleptic-like Rat ModelACCESS NewswireZÜRICH, SWITZERLAND / ACCESSWIRE / May 28, 2024 / NLS Pharmaceutics Ltd. , a Swiss clinical-stage biopharmaceutical company dedicated to
- 2y agoNLSPNLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from NasdaqACCESS NewswireZÜRICH, SWITZERLAND / ACCESSWIRE / May 24, 2024 / NLS Pharmaceutics Ltd. , a Swiss clinical-stage biopharmaceutical company focused on the
- 2y agoNLSPNLS Pharmaceutics Announces Receipt of Staff Delisting Determination from Nasdaq; Intends to Request HearingACCESS NewswireZÜRICH, SWITZERLAND / ACCESSWIRE / April 19, 2024 / NLS Pharmaceutics Ltd. , a Swiss clinical-stage biopharmaceutical company focused on the
- 2y agoNLSPNLS Pharmaceutics Announces Closing of $1.75 Million Registered Direct OfferingACCESS NewswireZÜRICH, SWITZERLAND / ACCESSWIRE / March 22, 2024 / NLS Pharmaceutics Ltd. , a Swiss clinical-stage biopharmaceutical company focused on the
- 2y agoNLSPNLS Pharmaceutics Announces $1.75 Million Registered Direct OfferingACCESS NewswireZURICH, SWITZERLAND / ACCESSWIRE / March 20, 2024 / NLS Pharmaceutics Ltd. , a Swiss clinical-stage biopharmaceutical company focused on the
- 2y agoNLSPNLS Pharmaceutics Secures Exclusive Global License for Next-Generation Non-Sulfonamide Dual Orexin Agonist PlatformACCESS NewswireThe exclusive License Agreement grants NLS Pharmaceutics global rights to next-generation non-sulfonamide orexin-1 / orexin-2 receptor agonists, tailored to target multiple pathways in neuropharmacological
- 2y agoNLSPNLS Pharmaceutics to Participate in the BIO-EUROPE Springtime Partnering EventACCESS NewswireZURICH, SWITZERLAND / ACCESSWIRE / March 14, 2024 / NLS Pharmaceutics Ltd. , a Swiss clinical-stage biopharmaceutical company focused on the
- 2y agoNLSPNasdaq Accepts NLS Pharmaceutics' Plan to Regain Listing ComplianceACCESS NewswireZURICH, SWITZERLAND / ACCESSWIRE / March 11, 2024 / NLS Pharmaceutics Ltd. , a Swiss clinical-stage biopharmaceutical company focused on the
- 2y agoNLSPNLS Pharmaceutics Submits Plan to Regain Listing Compliance With NasdaqACCESS NewswireZÜRICH, SWITZERLAND / ACCESSWIRE / February 23, 2024 / NLS Pharmaceutics Ltd. , a Swiss clinical-stage biopharmaceutical company focused on the
- 2y agoNLSPNotice of Deficiency with Nasdaq Continued Listing RequirementsACCESS NewswireZURICH, SWITZERLAND / ACCESSWIRE / January 12, 2024 / NLS Pharmaceutics Ltd. , a Swiss clinical-stage biopharmaceutical company focused on the